Marilyn Bulloch, PharmD, BCPS, FCCM, SPP

Articles by Marilyn Bulloch, PharmD, BCPS, FCCM, SPP

A meta-analysis suggests that long-term P2Y12 inhibitor monotherapy after percutaneous coronary intervention may offer superior protection against major adverse cardiac and cerebrovascular events compared with aspirin, without increasing major bleeding risk—potentially challenging current guideline recommendations for antiplatelet therapy beyond 1 year.

Latest Updated Articles